

L'inibizione di mTor in Oncologia

Milano, 21 marzo 2013

INT via Venezian 1 Aula A

13.00: Lunch di benvenuto

13.50: Apertura dei lavori

14.00-14.15: Introduction (*F.DeBraud*)

Moderatori: F.DeBraud, A.Berruti

14.15-14.45: Lecture: The role of m-Tor pathways in oncological disease (*G.Tortora*)

14.45-15.15: Lecture: Pharmacocynetic and pharmacodynamic of Everolimus (*R.Danesi*)

15.15-15.30: Discussion

15.30-15.50: Coffee break

Clinical activity in solid tumors

Moderatori: R.Buzzoni, M.Aglietta

15.50-16.10: Renal cell carcinoma (*E.Verzoni*)

16.10-16.30: Pancreatic endocrine tumors (*S.Pusceddu*)

16.30-16.50: Breast carcinoma (*S.di Cosimo*)

16.50-17.10: Clinical management and patient approach (*P.Grassi*)

17.10-17.45: Take home messages and Conclusions (*G.Procopio*)